Unsam advances in phase 1 studies

The University of San Martín and the Conicet advance in the development of a coronavirus vaccine that is about to start preclinical testing of the phase 1 if an agreement is concluded with a private laboratory, the institution clarified today in a statement.

« The vaccine that is developed in National University of San Martín (Unsam) moves forward with the preclinical phase with Very good results. What follows is to reach an agreement with a private laboratory to start phase 1, which is human testing, « said the rector. Carlos Greco.

« We had very strong support from the Technological Promotion Agency to get a strategic partner for the business sector, « said Greco and indicated that a preliminary agreement with a laboratory is in progress to finance this stage.

The Argentine vaccine against the coronavirus

In the statement distributed today by the Unsam It was reported that the project for a vaccine against coronaviruscarried out in that house of studies was among the 128 in the preclinical phase of the whole world.

« They all sought and seek the same goal: to immunize the population against SARS-Cov-2 virus, but they use different technologies « , explained from the group of scientists of the Unsam led by Juliana Cassataro, which has researchers from different specialties such as virology, immunology, infectious diseases, protein structure, among others.

As explained, the formula for this vaccine is based on recombinant proteins, a technology similar to that used in the Hepatitis B or HPV.

This proposal was selected and supported by the National Agency for the Promotion of Research, the Technological Development and Innovation (R + D + i Agency) within the framework of Coronavirus Unit that integrates together with the Ministry of Science, Technology and Innovation of the Nation and Conicet.

Unsam vaccine: when will it be ready?

Greco he had told Radio Cooperativa yesterday that « it is possible that within a year the Argentina have your own vaccine production without the need for negotiations with foreign laboratories. « 

« In the future it would mean a technological scientific sovereignty, when the production of the vaccine is reached that for this disease will mean that we will not depend on these complex negotiations with other international producers« Greco noted.